CreatorsPublishersAdvertisers

#Gastric Cancer

targetedonc.com

Nivolumab/Ipilimumab Arm Misses Mark While Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer

The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer. The combination of nivolumab/ipilimumab (Yervoy) did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer. However, the frontline combination...
CANCER
Picture for Nivolumab/Ipilimumab Arm Misses Mark While Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer
gastroenterologyadvisor.com

PPI Use May Be Associated With Gastric Cancer

Compared with the use of histamine-2 receptor antagonists (H2RAs), the use of proton pump inhibitors (PPIs) is associated with an increased risk for gastric cancer, although the absolute risk remains low, according to a study published in Gut. Previous observational studies suggest that PPI use is associated with an increased...
CANCER
Picture for PPI Use May Be Associated With Gastric Cancer
firstwordpharma.com

ESMO21: Opdivo, Yervoy combo falls short in head and neck, gastric cancer studies

The first detailed results from the CheckMate -651 trial showed that median overall survival (OS) for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who received the combination of Bristol Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) was 13.9 months versus 13.5 months for the EXTREME regimen of cetuximab, cisplatin/carboplatin and fluorouracil. The data were released ahead of presentation at the European Society for Medical Oncology (ESMO) congress.
CANCER
Picture for ESMO21: Opdivo, Yervoy combo falls short in head and neck, gastric cancer studies
TRENDING TOPICS
cancernetwork.com

Patients with Advanced Esophageal Cancers Benefit From Addition of Sintilimab

Results of 2 studies presented at 2021 ESMO demonstrate superior efficacy of sintilimab plus chemotherapy versus chemotherapy alone in certain gastrointestinal cancers. The addition of sintilimab (Tyvyt) to chemotherapy in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) or unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma was able to improve overall survival (OS) versus chemotherapy alone, according to results of 2 studies that were presented during the 2021 European Society for Medical Oncology Congress.1,2.
CANCER

AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial included HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma patients previously treated with a trastuzumab-containing regimen. Detailed results provided a clinically meaningful and...
CANCER
onclive.com

Nivolumab/Chemo Approaches EU Approval for Select HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.
CANCER
advfn.com

AstraZeneca Sees Positive Results for Enhertu Trial

Daiichi Sankyo (PK) (USOTC:DSNKY) AstraZeneca and Daiichi Sankyo Co. said they said the saw positive results from a Phase II trial that showed Enhertu provided a clinically meaningful and durable tumor response in patients with HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma previously treated with a trastuzumab-containing regimen.
MEDICAL & BIOTECH

Appealing Data Of CARsgen Therapeutics' CAR-T (CT041) In Advanced Gastric Cancer Presented At ESMO

SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been orally presented at the European Society of Medical Oncology Congress 2021 (ESMO 2021). The presenter was Dr. Changsong Qi from Beijing Cancer Hospital.
CANCER
cancernetwork.com

Limited Clinical Activity Attributed to Second-Line Treatment With Linagliptin Plus Atezolizumab in Gastric/GEJ Carcinoma

Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab. Second-line treatment with linagliptin (Tradjenta) plus atezolizumab (Tecentriq) for patients with locally or advanced metastatic gastric and gastroesophageal junction cancers resulted in limited clinical activity, according...
CANCER
targetedonc.com

Limited Clinical Activity in Second-Line Gastric/GEJ Cancer Seen With Linagliptin/Atezolizumab Combo

Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer were seen with Linagliptin plus atezolizumab. Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer were seen with Linagliptin (Tradjenta) plus atezolizumab...
CANCER

Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer

Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene Ltd’s (NASDAQ: BGNE) tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ). The data were presented at the European Society for Medical Oncology (ESMO21) Congress. Earlier...
HEALTH
ajmc.com

Samsung Bioepis Releases Positive 5-Year Follow-up Results for Trastuzumab Biosimilar

Samsung Bioepis found during a 5-year follow-up study that Ontruzant, the company’s trastuzumab biosimilar, had comparable cardiac safety and long-term efficacy with the reference product Herceptin. Five-year follow-up data show comparable safety and long-term efficacy profiles between Ontruzant (SB3), a trastuzumab biosimilar developed by Samsung Bioepis, and the reference product,...
MEDICAL & BIOTECH
firstwordpharma.com

ESMO21: Zymeworks gains on data for bispecific antibody in oesophageal cancer

Zymeworks said Thursday its HER2‑targeted bispecific antibody zanidatamab showed "promising response rates and durability" when paired with chemotherapy in a Phase II trial of first-line patients with gastroesophageal adenocarcinoma (GEA). The findings, which sent company shares rising as much as 10%, were presented at the European Society for Medical Oncology (ESMO) congress.
CANCER
streetwisereports.com

Leap Therapeutics Shares Skip Higher on Positive Preliminary Data From Gastric Cancer Study

Biotechnology company Leap Therapeutics Inc. (LPTX:NASDAQ), which concentrates its work on the development of targeted and immuno-oncology therapeutics, today announced "the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s (BGNE:NASDAQ; 06160:HKEX) anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress."
HEALTH
greenmedinfo.com

Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer.

Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer. Mingde Zang, Junyi Hou, Yakai Huang, Jiangli Wang, Xusheng Ding, Baogui Zhang, Yanong Wang, Yi Xuan, Ye Zhou. Article Affiliation:. Mingde Zang. Abstract:. Gastric cancer (GC) is one of the major causes of cancer-related deaths and...
CANCER
getnews.info

Gastric Cancer Therapeutic Assessment, Emerging Therapies, Clinical and Non-Clinical Studies, Key Companies, Treatment Algorithm, and Pipeline Analysis

Gastric Cancer Pipeline Insight, 2021″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Gastric Cancer Market. The Gastric Cancer Pipeline report embraces in-depth commercial and clinical assessment of the Gastric Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.
CANCER
evaluate.com

Esmo 2021 – Mahogany loses its polish for Macrogenics

Macrogenics is already struggling to justify a role for Margenza in Her2-positive breast cancer, and it seems that gastric tumours will prove no less difficult. New data in front-line gastroesophageal adenocarcinoma (GEA) at Esmo do not stack up favourably against Zymeworks’ zanidatamab – another anti-Her2 project hoping to take share from Roche’s Herceptin. In a phase 2 trial testing zanidatamab on top of three different chemotherapy regimens the bispecific antibody posted an objective response rate of 75%. Margenza, administered with Macrogenics’ anti-PD-1 MAb tretifanlimab, could only muster an ORR of 53% in module A of the phase 2/3 Mahogany trial. One caveat is that these are early data cuts, each concerning a few dozen evaluable Her2-positive patients, so the situation could shift. Still, Zymeworks’ stock rose 10% as the data boosted hopes for zanidatamab's potentially registrational phase 3 trial, which is to begin by year end. Macrogenics's shares, meanwhile, dropped 25%. Margenza’s best hope might be as a chemotherapy-free option in this setting, given the toxicity profile, according to the sellside. But Her2-positive gastric cancer is a small and crowded space, and the data need to get much better to look competitive.
CANCER

Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the interim analysis results of the Phase 3 ORIENT-16 study evaluating sintilimab in combination with chemotherapy compared to chemotherapy alone for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in an oral presentation at the ESMO (European Society for Medical Oncology) Congress 2021 (Abstract # LBA53).
CANCER
YOU MAY ALSO LIKE